China's Yabao Pharmaceutical Group Co., Ltd. and the Department of science and technology of the British Academy of Medicine (hereinafter referred to as MRCT) are jointly carrying out a preclinical cooperation that the western pharmaceutical industry and academia dare not set foot in to develop compounds against an unknown Parkinson's disease kinase target.
Bold attempts also have two sides. According to Michael Dalrymple, Western companies contracted by MRCT are in trouble because they see too many investment risks at this stage of the Parkinson's disease project. "We can't get motivated in the West because although companies find it interesting, this stage is too early for them," he said. "The inherent conservatives of Western pharmaceutical have the upper hand, but China is more excited to take further steps."
Dalrymple is the manager of the enterprise development department of MRCT, which is an independent organization responsible for the project technology transfer and transformation of the technology transfer needs of the British Medical Research Council. Similarly, Dalrymple said that many academic institutions and organizations are still trembling with Chinese companies in the program cooperation at the development stage. He is worried that the next project will be terminated because China's R & D infrastructure is not as perfect as that in the West. However, he believes that this alliance can bring an opportunity for Yabao to expand its capacity and build trust in his organization. He hopes to bring more cooperation benefits in the future.
In this cooperation announced in late November, MRCT will provide non patented technologies related to the structure, primary and secondary screening tests of the compound, and cooperate with Yabao in preclinical strategy and experimental design. Yabao will carry out experiments and promise to invest in R & D to meet the needs of the project. AlPO has the right to explore, develop and commercialize products through cooperation with Chinese mainland, Taiwan and Hongkong. MRCT reserves the right to all other markets. According to Dalrymple, the deal includes standard milestone fees and royalties. None of these partners disclosed financial details.
The agreement is one of the two agreements recently signed by MRCT and Chinese enterprises. This month, the organization also announced the cooperation with Shandong International Biotechnology Park to develop a product to deal with Alzheimer's disease (AD). Dalrymple told scibx that when the Parkinson's disease project encountered obstacles, he began to look for partners because it needed more resources than MRCT had. "It's about partners who share your vision with you using resources we don't have internally," he said.
He added that a large number of Chinese companies are interested in cooperation, and many of them have little ability and practical experience in "western innovation". However, Yabao stands out for MRCT to some extent because of its R & D general manager Wang Peng. As a returnee who has been in the United States for nearly 20 years, President Wang brought four years of CSO experience in Xiansheng pharmaceutical and four years of drug development experience in Wuxi apptec. President Wang told scibx that he wanted to use the Parkinson's disease program as a carrier to develop Yabao's internal infrastructure and external alliances, which could be used as part of his strategy to bring the Western R & D model into the company.
请将简历发送至：